**Dapsone- and nitroso dapsone-specific activation of T-cells from hypersensitive patients expressing the risk allele HLA-B\*13:01**

**Short title:** HLA allele-restricted T-cell responses to drugs

**Authors:** Qing Zhao,1,2,3,4 Khetam Alhilali,1,4 Abdulaziz Alzahrani,1,4,5 Mubarak Almutairi,1 Juwaria Amjad,1 Hong Liu,2,3 Yonghu Sun,2,3 Lele Sun,2,3 Huimin Zhang,2,3 Xiaoli Meng,1 Andrew Gibson,1 Monday O Ogese,1,6 B. Kevin Park,1 Jianjun Liu,7 David A. Ostrov,8 Furen Zhang,2,3\* Dean J. Naisbitt.1\*

4 each author contributed equally to the manuscript

1MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The University of Liverpool, Liverpool, L69 3GE, England; 2Department of Dermatology, Shandong Provincial Hospital for Skin Disease, Shandong University, Jinan, Shandong 250022, China; 3Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong 250022, China; 5Al Baha University, Prince Mohammad Bin Saud, Al Bahah 65527, Saudi Arabia; 6Pathological Sciences, drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, UK. 7Human Genetics, Genome Institute of Singapore, A\*STAR, 138672, Singapore; 8Department of Pathology, Immunology and Laboratory Medicine, University of Florida, College of Medicine, Gainesville, Florida, USA.

\*Correspondence shared between Professors Dean J. Naisbitt (The University of Liverpool, Liverpool, England [Telephone, 0044 151 7945346; e-mail, dnes@liv.ac.uk]) and

& Furen Zhang (Shandong Provincial Hospital for Skin Disease, Shandong University, Jinan, Shandong, China. [Telephone, +86 531 87298801; e-mail, zhangfuren@hotmail.com]).

**Word count:** 3879

**Abstract**

**Background:** Research into drug hypersensitivity associated with expression of specific HLA alleles has focussed on the interaction between parent drug and the HLA with no attention given to reactive metabolites. For this reason, we have studied HLA-B\*13:01-linked dapsone hypersensitivity to (1) explore whether the parent drug and/or nitroso metabolite activates T-cells and (2) determine whether HLA-B\*13:01 is involved in the response.

**Methods:** PBMC from 6 patients were cultured with dapsone and nitroso dapsone and proliferative responses and IFN-γ release were measured. Dapsone- and nitroso dapsone-specific T-cell clones were generated and phenotype, function, HLA allele restriction and cross-reactivity assessed. Dapsone intermediates were characterized by mass spectrometry.

**Results:** PBMC from 6 patients and cloned T-cells proliferated and secreted Th1/2/22 cytokines when stimulated with dapsone (clones: n=395; 80% CD4+ CXCR3hiCCR4hi, 20% CD8+CXCR3hiCCR4hiCCR6hiCCR9hiCCR10hi) and nitroso dapsone (clones: n=399; 78% CD4+, 22% CD8+ with same chemokine receptor profile). CD4+ and CD8+ clones were HLA-class II and class I restricted, respectively, and displayed three patterns of reactivity: compound-specific, weakly crossreactive and strongly cross reactive. Nitroso dapsone formed dimers in culture and was reduced to dapsone, providing a rationale for the crossreactivity. T-cell responses to nitroso dapsone were dependent on the formation of a cysteine-modified protein adduct, while dapsone interacted in a labile manner with antigen presenting cells. CD8+ clones displayed an HLA-B\*13:01-restricted pattern of activation.

**Conclusion:** These studies describe the phenotype and function of dapsone- and nitroso dapsone-responsive CD4+ and CD8+ T-cells from hypersensitive patients. Discovery of HLA-B\*13:01-restricted CD8+ T-cell responses indicates that drugs and their reactive metabolites participate in HLA allele-linked forms of hypersensitivity.

**Keywords:** Human, T-cells, drug hypersensitivity.

**Key messages:** (1) Dapsone and nitroso dapsone activate CD4+ and CD8+ T-cells from hypersensitive patients via different mechanisms: (2) Dapsone and nitroso dapsone interact with HLA-B\*13:01 to activate certain CD8+ clones: (3) Dapsone hypersensitivity should be used as an exemplar to solve the structure of drug metabolite-modified peptide HLA interactions and the relationship between HLA binding and T-cell activation.

**Introduction**

Genome-wide association studies have identified strong associations between expression of HLA alleles and susceptibility to drug hypersensitivity (1). These data suggest that drugs bind selectively to the HLA protein to activate the T-cells that participate in the adverse event. Molecular docking studies support this concept (2, 3); however, modelling data has to be interpreted with caution as the nature of the drug HLA protein interaction and the requirement for a specific peptide in the binding groove has not been determined. The most robust genetic associations are between HLA class I alleles and abacavir hypersensitivity (4), flucloxacillin liver injury (both HLA-B\*57:01) (5), carbamazepine-induced Stevens Johnson syndrome (HLA-B\*15:02) (6) and allopurinol hypersensitivity (HLA-B\*58:01) (8) and in each case mechanistic studies have shown that CD8+ T-cells are activated when the drug interacts with the relevant HLA protein (8-12). For abacavir and carbamazepine, the drug HLA binding site is very different; abacavir binds deep in the HLA peptide binding pocket, while carbamazepine binds to a site closer to the T-cell receptor interface. Despite this, both drugs interact with HLA proteins via a reversible interaction to stimulate T-cells. T-cells from patients with allopurinol hypersensitivity are activated with a stable metabolite, oxypurinol, also via a direct binding interaction with HLA. In contrast, flucloxacillin-specific T-cells from patients with liver injury are activated with drug-protein adducts, via a hapten mechanism involving the spontaneous binding of the drug to protein and antigen processing. This brief discussion illustrates that rapid progress has been made in our understanding of the relationship between drug HLA binding and the activation of T-cells; however, reactive drug metabolites have been ignored in the study of HLA allele-restricted forms of drug hypersensitivity. This is primarily because of the absence of synthetic reactive metabolites for functional studies with T-cells from hypersensitive patients.

A reactive metabolite of sulfamethoxazole is known to activate patient T-cells via a hapten mechanism (13-15); however, sulfamethoxazole reactions are not associated with a specific HLA allele. Thus, we recently synthesized the nitroso metabolite of dapsone and studied the priming of naïve T-cells from healthy donors (16). Dapsone contains a sulfone group that links two aromatic amine moieties. Oxidative metabolism of the amine groups generate a hydroxylamine. The hydroxylamine undergoes spontaneous oxidation to form nitroso dapsone, which binds covalently to cellular proteins (17, 18). Naïve CD4+ and CD8+ T-cells from healthy donors are activated with the parent drug and nitroso metabolite when Tregs were removed and the compounds were presented by dendritic cells (16). These data show that both forms of the drug interact with multiple HLA molecules and have the capacity to stimulate T-cells when regulatory pathways have been manipulated.

Dapsone is used in combination with other drugs for the treatment of infectious diseases such as leprosy and malaria. 0.5-3.6% of treated patients develop a hypersensitivity syndrome characterized by fever, skin rash and internal organ involvement 4-6 weeks after treatment commences (19). HLA-B\*13:01 is associated with the development of dapsone hypersensitivity in Chinese and Thai patients (20, 21), and modelling data suggests that dapsone may fit in the peptide recognition site of HLA-B\*13:01 (22). Dapsone-treated cell lines expressing HLA-B\*13:01 have been shown to activate T-cells, while PBMC from 2 / 7 patients secrete high levels of the cytolytic molecule granulysin when stimulated with the drug (23). Despite this, a detailed analysis of the phenotype and function of dapsone-specific T-cells has not been performed. Moreover, the activation of patient T-cells with nitroso dapsone has not been investigated. Thus, our study had three primary objectives: to investigate whether dapsone and/or nitroso dapsone activates CD4+ and CD8+ T-cells from hypersensitive patients; to define phenotype and function of drug-specific T-cells and to explore whether HLA-B\*13:01 is directly involved in the drug-/drug metabolite-specific T-cell response.

**Methods**

**Human subjects**

Venous blood (50ml) was collected from 6 dapsone hypersensitive patients. Table 1 summarizes the demographics of the patients. Supplementary Table 1 shows results of HLA typing. HLA-B\*13:01+ donors (n=4) with no history of dapsone exposure and HLA-B\*13:01+ dapsone tolerant patients (n=4) were selected as a control groups. Patch testing was conducted on the back of patients with dapsone (0.1-25%). The patch was removed after 48h. Results were recorded after a further 24h to exclude any false positive responses resulting from the patch tape. The study was approved by the Ethical Committee of the Shandong Provincial Institute of Dermatology and Venereology and informed written consent was obtained. A material transfer agreement was signed prior to shipment of PBMC to Liverpool.

**Lymphocyte transformation test and PBMC ELIspot**

PBMC (1.5x105 cell/well) from hypersensitive patients and control donors were incubated with dapsone (125-500µM), nitroso dapsone (10-40µM), rifampicin (10-100µM), clofazimine (10-100µM) or tetanus toxoid (5μg/mL, as a positive control) in culture medium for 5 days. [3H]thymidine was added for the final 16h of the experiment. IFN-γ, secreting PBMC were visualized using ELIspot by culturing PBMC (5x105 cell/well) in medium with/without optimal concentrations of dapsone or nitroso dapsone for 48h.

**Generation and characterization of drug-specific T-cell clones**

Dapsone and nitroso dapsone-responsive T-cell clones were generated from patients 5, 6 and 8 by serial dilution and characterized in terms of cellular phenotype (CD, TCR Vβ and chemokine receptors [flow cytometry]), secretion of cytokines and cytolytic molecules (ELIspot), antigen specificity (dose-response studies and crossreactivity with structurally-related compounds [3H]thymidine uptake]), pathways of activation (antigen presenting cell pulsing experiments, fixation of antigen presenting cells to block processing and addition of glutathione to block drug metabolite protein binding) and the involvement of HLA-B\*13:01 in the T-cell response (HLA antibody blocking experiments and use of partly HLA matched antigen presenting cells). Detailed methods are available in as supplementary material.

**Statistics**

All statistical analysis (One-way ANOVA unless stated otherwise) was performed using SigmaPlot 12 software (\*P<0.05).

**Results**

**Patch testing and *in vitro* activation of hypersensitive patient PBMC**

After 72 h drug exposure, 3 out of 6 patients displayed dapsone concentration-dependent positive readings (Figure 1a). PBMC from all 3 patch test positive patients were stimulated to proliferate strongly in the presence of dapsone and nitroso dapsone (Figure 1b). Positive dapsone-specific proliferative responses (SI 2 or above) and/or IFN-γ secretion were also detected with PBMC from the 3 patch test negative patients, while nitroso dapsone responses were detected in 2 patients (Figures 1b-d). Of note, patient 7 displayed a negative nitroso dapsone lymphocyte transformation test response on initial testing (Figure 1b) and a weak response when the assay was repeated (Figure 1d). PBMC were not activated with the co-medications rifampicin and clofazimine (Figure 1d). PBMC from dapsonenaïve (SI less than 2) and dapsone tolerant (SupplementaryFigure 1) HLA-B\*13:01+ controls proliferated in the presence of phytohemagglutinin, but not the test drugs.

**Dapsone and nitroso dapsone activate CD4+ and CD8+ clones**

A total of 1334 and 1374 CD4+ and CD8+ clones, respectively, were expanded from dapsone and nitroso dapsone T-cell lines from patients 5, 6 and 8. 626 CD4+ clones displayed reactivity against dapsone or nitroso dapsone (SupplementaryFigure 2). Dapsone- and nitroso dapsone-specific CD8+ clones were generated in lower numbers; 168 were activated with either the drug or drug metabolite. Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were detected in equal numbers (Table 2).

102 well-growing clones were selected for dose-titration studies and the analysis of cytokine secretion. Proliferative responses were detected with 3 well tolerated concentrations of dapsone (125-500µM) and nitroso dapsone (5-20µM) and drug treatment resulted in the secretion of Th1 (IFNγ), Th2 (IL-5, IL-13) and Th22 (IL-22) cytokines, alongside the cytolytic molecules perforin, granzyme B and FasL. CD4+ and CD8+ clones secreted similar levels of cytokines and cytolytic molecules (Figure 2). Supplementary Table 3 shows the percentage of DDS- and DDS-NO-responsive CD4+ and CD8+ clones that secrete individual cytokines.

**Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones display three distinct patterns of crossreactivity**

63 dapsone- and 98 nitroso dapsone-responsive CD4+ and CD8+ clones were assayed for crossreactivity. When all of the dapsone-responsive clones were assessed together, low levels of proliferation was observed with nitroso dapsone (Figure 3a). The maximum concentration of nitroso dapsone used was 10 times lower than the dapsone concentration. Analysis of individual clones revealed three distinct crossreactivity patterns; dapsone-specific, and weakly and strongly crossreactive with nitroso dapsone. Approximately 90% of the clones were dapsone-specific or weakly crossreactive (Figure 3b and c).

Nitroso dapsone CD4+ and CD8+ clones displayed a much higher level of crossreactivity (Figure 3a). However, 3 patterns of crossreactivity were again observed with individual clones; nitroso dapsone-specific, and weakly and strongly crossreactive with dapsone. In contrast to the dapsone-responsive clones, approximately 90% of the nitroso dapsone-responsive clones were nitroso dapsone-specific or highly crossreactive Figure 3b and c).

Dapsone- and nitroso dapsone-responsive clones were also stimulated to proliferate with dapsone hydroxylamine; however, proliferative responses were not detected when clones were cultured with (1) dapsone analogues with substitutions in the sulfone group, (2) dapsone analogues with amine groups in different positions on the aromatic rings and (3) structurally distinct sulfonamide antimicrobials (SupplementaryFigure 3).

The stability of nitroso dapsone in the proliferation assay was assessed. Nitroso dapsone was converted rapidly to azoxy dimers and the parent compound. Both compounds were detectable within 10min. After 2 days, 50% of nitroso dapsone had been converted to dapsone (Figure 3d-e).

**Crossreactive clones are activated with equivalent concentrations of dapsone and nitroso dapsone**

6 strong and weakly crossreactive clones were incubated with dapsone and nitroso dapsone at concentrations of 0.1-100µM to define the minimum stimulatory concentrations of the two compounds. Clones were stimulated to proliferate with equivalent concentrations of each compound irrespective of the extent of crossreactivity (Figure 4).

**Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones expressing multiple TCR Vβ chains display distinct chemokine receptor profiles**

Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones expressed single, but variable TCR Vβ chains (SupplementaryFigure 4a), with no clear differences discernible when CD4+ and CD8+ or dapsone- and nitroso dapsone-responsive clones were compared. Dapsone- and nitroso dapsone-responsive CD4+ clones expressed high levels of the chemokine receptors CXCR3 and CCR4. The CD8+ clones expressed CXCR3 and CCR4 alongside CCR10, CCR9 and CCR6 (SupplementaryFigure 4b).

**HLA-restricted activation of dapsone- and nitroso dapsone-responsive clones ensues via different mechanisms**

Stimulation of dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones was dependent on the presence of antigen presenting cells (Figure 5a). Use of blocking antibodies revealed that CD4+ and CD8+ proliferative responses to dapsone and nitroso dapsone were HLA class II and I restricted, respectively (Figure 5b). Fixation of antigen presenting cells with glutaraldehyde had no effect on the activation of CD4+ or CD8+ clones with dapsone. In contrast, antigen presenting cell fixation reduced the extent of proliferation with the nitroso metabolite (Figure 6a). The residual response detected with nitroso dapsone and fixed antigen presenting cells relates to the conversion of nitroso dapsone to dapsone in culture.

Nitroso dapsone-responsive CD8+ clones were activated with antigen presenting cells pulsed with nitroso dapsone for 0.5-2h (Figure 6b). 2 out of 4 nitroso dapsone-responsive CD4+ clones were also stimulated to proliferate with nitroso dapsone-pulsed antigen presenting cells. Antigen presenting cells pulsed with dapsone for 0.5-2h did not activate the dapsone-responsive CD4+ or CD8+ clones.

SupplementaryFigure 5a compares the level of nitroso dapsone glutathione adducts formed in the cell culture assay in the presence and absence of exogenous glutathione (24, 25). Adducts were formed rapidly (within 2h) and the level of adduct formation was several orders of magnitude higher in the presence of exogenous glutathione. SupplementaryFigure 6 contains traces showing how the adducts were quantified. The addition of glutathione to the T-cell assay containing soluble nitroso dapsone reduced the strength of the proliferative response, while the response to nitroso dapsone-pulsed antigen presenting cells was completely blocked (SupplementaryFigure 5b).

**Dapsone and nitroso dapsone bind with a degree of selectively to HLA-B\*13:01 to activate certain CD8+ T-cell clones**

EBV-transformed B-cells were generated from 9 healthy donors expressing HLA alleles with greater than 90% sequence homology to HLA-B\*13:01. HLA typing of the healthy donors is shown in Supplementary Table 2. The B-cell lines were used to explore the requirement for HLA-B\*13:01 in dapsone- and nitroso dapsone-specific CD8+ T-cell activation. Autologous antigen presenting cells and antigen presenting from 1 additional patients were used as comparators.

As has been described previously for other drugs (26, 27), 30% of dapsone and nitroso dapsone-responsive HLA-class I restricted CD8 clones displayed proliferative responses with the drug or metabolite and antigen presenting cells expressing a wide variety of HLA alleles (results not shown). Other clones were activated with the drug or metabolite only in the presence of autologous antigen presenting cells. Despite this, 30-40% of CD8+ clones displayed a degree of HLA-B\*13:01 allele restriction. Figure 7a and b shows 3 clones (1 dapsone- and 2 nitroso dapsone-responsive) that were stimulated to proliferate exclusively in the presence of dapsone or nitroso dapsone and antigen presenting cells expressing HLA-B\*13:01. Three additional clones (1 dapsone- and 2 nitroso dapsone-responsive) are shown that were activated in the presence of antigen presenting cells expressing HLA-B\*13:01 and either B\*13:02, B\*58:01 or B\*51:01.

The 2 dapsone responsive CD8+ clones were expanded in sufficient numbers for us to conduct a proliferation assay using antigen presenting cells from the 6 hypersensitive patients that all express HLA-B\*13:01. The clones were activated in the presence of dapsone and antigen presenting cells from all of the patients (Figure 7c).

**Discussion**

Knowledge of the role drug metabolism plays in the generation of antigenic determinants that activate T-cells is limited. Circumstantial evidence supporting a role for drug metabolism includes the identification of protein-reactive metabolites for many drugs associated with a high incidence of hypersensitivity and the induction of toxicity in target tissue by reactive metabolites and hence the potential to disrupt immune regulatory pathways through the provision of danger signals (28). However, the most direct evidence linking drug metabolism to the development of hypersensitivity is the detection of halothane-specific antibodies in patients with liver failure (29) and the observation that halothane protein adducts activate T-cells (30). Furthermore, halothane derivatives that form lower levels of reactive metabolite are associated with a decreased risk of liver injury (31). To explore whether metabolites activate hypersensitive patient T-cells *in vitro,* co-culturestrategies have been developed using microsomal metabolite generating systems (32, 33). Enhanced drug-specific T-cell responses have been reported with drugs in the presence of a metabolising system; however, it is very difficult to delineate the disparate effects of the parent drug and metabolites. For this reason, we synthesized the reactive metabolite of sulfamethoxazole (34), which causes immune-mediated skin and liver reactions that are not linked to expression of a specific HLA allele (35, 36). Working alongside other researchers in the field we have shown that PBMC and inflamed tissue from all hypersensitive patients contain T-cells that are activated with sulfamethoxazole and/or its reactive metabolite via different pathways (i.e., direct HLA binding and a hapten pathway, respectively) (13-15).

In recent years, researchers studying hypersensitivity reactions strongly linked to expression of specific HLA alleles have focussed exclusively on the interaction between parent drug and the HLA molecule. This is because the parent drug is, for the most part, the only reagent available for *in vitro* cell culture studies. The observation that T-cells from patients with hypersensitivity to drugs such as carbamazepine are activated with the parent drug (12), has lead researchers to hypothesize that reactive metabolites are not involved in the development of HLA allele-restricted forms of drug hypersensitivity. To investigate this hypothesis we now focused on dapsone hypersensitivity in patients with leprosy. Dapsone is a model study drug as hypersensitivity reactions in patients are strongly linked to expression of HLA-B\*13:01 (20), the reactive nitroso metabolite of dapsone has been synthesized in a stable form (16) and patient samples are available for mechanistic studies. Utilizing PBMC from HLA-B\*13:01+ patients we show CD4+ and CD8+ T-cell responses to dapsone and the nitroso metabolite. Furthermore, dapsone and nitroso dapsone bind to HLA-B\*13:01 to selectively activate certain CD8+ clones.

Six HLA-B\*13:01+ patients that developed hypersensitivity whilst receiving dapsone in combination with rifampicin and clofazimine were recruited to the study. Three displayed a positive patch test response to dapsone. PBMC from all six patients were stimulated to proliferate and/or secrete IFN-γ after stimulation with dapsone or the nitroso metabolite. The strongest *in vitro* responses were seen in the patients with the positive patch test response and these patients were selected for serial dilution experiments to search for drug- and drug metabolite-responsive T-cell clones.CD4+ and CD8+ sub-populations were purified before plating single cells in culture plates for the cloning procedure. Dapsone- and nitroso dapsone-responsive T-cells were generated in almost equal numbers (dapsone 395; nitroso dapsone 399). The ratio of dapsone- or nitroso dapsone-responsive CD4+ and CD8+ T-cell clones was 4-5:1 in patients 6 and 8 and 2:1 in patient 5, which demonstrates that drug exposure consistently results in CD4+ and CD8+ responses against the drug antigens. This is in stark contrast to the findings with abacavir where CD8+ T-cells are the only cells activated with the drug (37-39). The activation of CD4+ and CD8+ clones that expressed an array of TCR Vβ receptors, with dapsone or nitroso dapsone, was HLA class II and class I restricted, respectively. This confirms our previous data with PBMC from healthy donors (16), which shows that both dapsone and nitroso dapsone interact with HLA class I and class II molecules.

The availability of cloned CD4+ and CD8+ T-cells permitted the detailed analysis of crossreactivity between dapsone, nitroso dapsone and structurally-related compounds, mechanisms of dapsone- and nitroso dapsone-specific T-cell activation and the involvement of the allele HLA-B\*13:01 in antigen presentation. Crossreactivity studies revealed that the position of the amine groups on the aromatic rings of dapsone and the availability of the sulfone group was critical for the activation of the T-cell clones. Furthermore, as a panel of sulfonamides that contain one aromatic amine group did not activate the clones, both of dapsones’ aromatic amines were required for T-cell activation.

25-50% of CD4+ and CD8+ clones were classified as highly specific as they were only activated with one compound (either the parent drug or metabolite [Figure 3b]). This confirms that T-cells recognize and respond selectively to the two different forms of the dapsone antigen. Dapsone has an unusual structure in that the two aromatic amines connected to the sulfone group are identical. If the structure of a nitroso dapsone-modified HLA binding peptide is compared with dapsone complexed to the same peptide, it is likely that similar conformations will be observed and as such the interaction with the T-cell receptor will be the same. Thus, our working hypothesis to explain the drug- or drug-metabolite-specific activation of certain clones is that the HLA binding peptides also participate in the TCR interaction and impart a degree of selectivity.

When using optimum concentrations of dapsone (100-500µM) and nitroso dapsone (5-20µM) to activate CD4+ and CD8+ T-cells, clones displaying high (i.e., at least 50% of the response detected with the opposite compound) and low (i.e., 10-50% of the response detected with the opposite compound) levels of crossreactivity were also detected. The majority of dapsone-responsive, crossreactive CD4+ and CD8+ clones displayed low levels of crossreactivity with nitroso dapsone. Using quantitative mass spectrometry we were able to demonstrate that the nitroso metabolite is reduced to dapsone in the 2 day proliferation assay. Thus, clones incubated with 30µM nitroso dapsone were exposed to 2.5-15µM of the parent drug, which stimulates a sub-optimal T-cell proliferative response. In contrast, the majority of crossreactive nitroso dapsone-responsive CD4+ and CD8+ clones displayed high levels of crossreactivity with 100-500µM dapsone. To investigate the response profiles further, a panel of crossreactive dapsone- and nitroso dapsone-responsive clones were cultured with equal concentrations of the parent drug and metabolite (0.1-100µM). Interestingly, weakly and strongly crossreactive clones were activated with the same concentrations of dapsone and nitroso dapsone with similar dose-response curves until nitroso metabolite-induced toxicity was detected. These data are in contrast to our earlier studies with sulfamethoxazole and its nitroso metabolite, where the parent drug activates T-cells at significantly higher concentrations (14). It is reasonable to assume that HLA binding peptides play a less important role in the triggering of crossreactive TCR.

Given that clones displaying reactivity towards dapsone and/or the nitroso metabolite were detected, it was important to define mechanisms of antigen presentation including the requirement for antigen processing. Antigen presenting cells were required for the strong activation of CD4+ and CD8+ clones with dapsone and the nitroso metabolite. Clones were activated with dapsone in the presence of irradiated and glutaraldehyde-fixed antigen presenting cells. In contrast, fixation reduced the strength of the nitroso dapsone-specific T-cell proliferative response. This suggests that dapsone activates T-cells through a direct interaction with HLA molecules, whereas nitroso dapsone binds covalently to cellular protein forming adducts that require processing to generate antigenic peptides. As discussed above, the best explanation for the weak response of nitroso dapsone-responsive clones with soluble nitroso dapsone and fixed antigen presenting cells is the formation of dapsone in the proliferation assay. The drug-specific activation of clones from dapsone hypersensitive patients by two pathways has important implications for the future structural analysis of how dapsone and nitroso dapsone interacts with HLA molecules. Application of drug- or drug metabolite-pulsed antigen presenting cells instead of soluble drug in T-cell assays provides a tool to differentiate between the effects of covalent and non-covalent forms of drug (15, 40). Dapsone-responsive clones were not activated with dapsone-pulsed antigen presenting cells. In contrast, 6 out of the 8 nitroso dapsone-responsive clones tested were activated with nitroso dapsone-pulsed antigen presenting cells and the strength of the induced response was the same as that seen with the parent drug. Two of the nitroso dapsone-responsive clones were not activated with pulsed antigen presenting cells; interestingly, both of these clones crossreacted strongly with dapsone.

Glutathione is a tripeptide intracellular antioxidant that protects cells from exposure to aromatic nitroso compounds by acting as a reducing agent and through direct conjugation (24, 25). The addition of glutathione to T-cell assays prevents the covalent binding of nitroso compounds and hence it is possible to explore whether T-cells are activated with drug metabolite-modified protein adducts (41). Nitroso dapsone glutathione adducts were formed rapidly in cultures containing the drug metabolite, T-cells, antigen presenting cells and glutathione. Moreover, glutathione decreased the response of clones to soluble nitroso dapsone and blocked the response to nitroso dapsone-pulsed antigen presenting cells. Thus, the formation of a covalent adduct between nitroso dapsone and cellular proteins is needed for the activation of certain clones.

In the next section of the project, antigen presenting cell were generated from healthy donors expressing HLA-B alleles with at least 90% sequence homology to HLA-B\*13:01 (including an additional HLA-B\*13:01+ donor) to investigate whether either dapsone or nitroso dapsone interact with a degree of selectivity to the risk allele to activate CD8+ clones. As described previously with other forms of drug hypersensitivity, several clones displayed HLA allele-unrestricted drug recognition (i.e., dapsone and nitroso dapsone stimulated a proliferative response in the presence of multiple antigen presenting cells expressing different HLA-B alleles) (26). Other clones were only activated in the presence of nitroso dapsone and autologous antigen presenting cells. However, a panel of clones were selectively activated with dapsone or nitroso dapsone in the presence of antigen presenting cells displaying HLA-B\*13:01. Crossreactivity was observed for several of these clones; however, no predominant TCR Vβ receptors were expressed. This indicates that both the parent drug and reactive metabolite interacts with HLA-B\*13:01 to activate certain CD8+ clones. We are therefore synthesizing designer nitroso dapsone-modified HLA-B\*13:01 binding peptides and conducting structural analyses to compare the binding interaction of dapsone and nitroso dapsone with HLA-B\*13:01.

Different forms of drug hypersensitivity reaction is associated with the secretion of a diverse panel of cytokines from T-cells (42) Thus, ELIspot was used to profile cytokine secretion from dapsone- and nitroso dapsone-stimulated clones. CD4+ and CD8+ clones secreted the same panel of cytokines when stimulated with dapsone or nitroso dapsone, but expressed distinct chemokine receptors. Clones secreted Th1, Th2 and Th22 cytokines alongside the cytolytic molecules perforin, granzyme B and FasL; however, IL-17 was not detected. IL-22 secretion in the absence of IL-17 seems to be a common feature of drug-specific clones as this profile has now been detected with dapsone, sulfamethoxazole and piperacillin (43, 44). It is possible that this profile relates to the long-term *in vitro* culture of clones; thus, a future study exploring the cytokine profile in affected tissues would be appropriate. The chemokine receptors displayed on dapsone- or nitroso dapsone-responsive CD4+ clones was restricted to CXCR3 and CCR4. In contrast, CD8+ clones also expressed CCR6, 9 and 10. CCR4 and CCR10 have been implicated in the migration of T-cells into skin (45); thus, a more detailed investigation of migratory properties of CD4+ and CD8+ T-cells in patients with dapsone hypersensitivity is warranted.

In conclusion, our study shows that dapsone- and nitroso dapsone-responsive CD4+ and CD8+ T-cells circulate in hypersensitive patients. T-cells were activated selectively with the parent drug and drug metabolite via direct HLA binding and a hapten mechanism, respectively. The detection of HLA-B\*13:01-restricted dapsone- and nitroso dapsone-responsive CD8+ clones indicates that dapsone hypersensitivity should be used as an exemplar to explore the structural features of drug HLA binding and how this interaction results in a pathogenic T-cell response. For patients with suspected hypersensitivity, it is critical to identify the agent that caused the reaction. We are currently exploring whether drug-peptide antigens represent effective reagents for T-cell activation. A better understanding of drug antigenicity will lead to the development of improved evidence-based diagnostic tools.

**Acknowledgements:** The authors would like to thank the patients and volunteers for agreeing to donate blood and tissue samples.

**Funding:** This work was funded by grants from the MRC (grant number MR/R009635/1), the National Key Research and Development Program of China (2016YFE0201500), the National Natural Science Foundation of China key program for international exchange and coorperation (81620108025), the National Natural Science Foundation of China (81703110, 81701579), the Key research and development program of Shandong Province (2016ZDJS07A06), the Natural Science Foundation of Shandong Province (JQ201616), the National Clinical Key Project of Dermatology and Venereology, the Shandong Provincial Advanced Taishan Scholar Construction Project, and the Innovation Project of Shandong Academy of Medical Science. Central funds were obtained from the MRC Centre for Drug Safety Science (G0700654).

**Author contributions:** QZ, KA, AA, MA, JA, AG and MOO conducted the biological experiments. XM conducted the mass spectrometric analyses. HL, LD and HZ collected the clinical samples and conducted patch testing. DJN, BKP, DAO, JL and FZ designed the study and supervised the project. AG, MOO, XM and DJN analysed the data and drafted the manuscript. All authors critically reviewed the manuscript.

**Conflicts of interest:** The authors declare no competing financial interest.

**Abbreviations**

Antigen presenting cells, APC; dapsone, DDS; nitroso dapsone, DDS-NO; stimulation index, SI; PBMC, peripheral blood mononuclear cells.

**Figure legends**

**Figure 1: Diagnosis of dapsone hypersensitivity by skin testing and *in vitro* assays.** (a) Skin patch test results for dapsone hypersensitivity. Skin was exposed to dapsone in polyethylene glycol 200 at dilutions of 0, 0.1, 0.5%, 1, 5, 10, 15, 2%, and 25%. The patch tape was left to the skin for 48 hours and diagnosis was made 24 hours later. Red ovals show areas of inflamed skin. (b) PBMC from patients were exposed to graded concentrations of dapsone or nitroso dapsone. Proliferation was measured after 5 days by the addition of [3H]thymidine for 16h. Results are expressed as mean±SD cpm of triplicate cultures. A doubling of cpm in drug-treated cultures over vehicle control is considered positive. (c) PBMC from patients were exposed to optimal concentrations of dapsone or nitroso dapsone and IFN-γ release was visualized by ELIspot. (d) PBMC from patients were exposed to graded concentrations of dapsone, nitroso dapsone, rifampicin and clofazimine. Proliferation was measured as described in (b) (DDS, dapsone; DDS-NO, nitroso dapsone; PHA, phytohaemagglutinin).

**Figure 2. Proliferative response and cytokine release by dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones.** (a) One hundred and two CD4+ or CD8+ clones were incubated with autologous antigen presenting cells and either dapsone (125-500µM) or nitroso dapsone (5-20µM) in triplicate cultures for 48h. Proliferative responses were measured by the addition of [3H]thymidine. Results are expressed as mean±SD cpm of the indicated number of clones. (b) Detection of IFN-γ, IL-5, IL-13, IL-17, IL-22, granzyme B, perforin and Fas-ligand secretion by dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones. Clones were incubated with autologous antigen presenting cells and either dapsone or nitroso dapsone and cytokine release was visualized by ELIspot. (c) Representative ELIspot images showing the cytokines released by dapsone and nitroso dapsone-responsive CD8+ clones.

**Figure 3: Crossreactivity of dapsone- and nitroso dapsone-responsive T-cell clones.** Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with irradiated autologous EBV-transformed B-cells and either dapsone (100-500µM) or the nitroso metabolite (5-20µM) in triplicate cultures for 48h. T-cell proliferative responses were assessed through the addition of [3H]-thymidine. (a) Mean crossreactivity data for 153 clones divided according to the drug antigen PBMC were cultured with to generate clones and CD phenotype. (b) Pie charts showing number of clones with a particular crossreactivity profile (compound specific, weekly crossreactive (crossreactive compound displaying 10-50% response detected with comparator) and strongly crossreactive (crossreactive compound displaying greater than 50% response detected with comparator). (c) Representative clones displaying each response profile. (d) Relative quantification of dapsone and azoxy dimer in cultures containing nitroso dapsone (30µM), autologous EBV-transformed B-cells and T-cell clones. (e) Absolute quantification of dapsone formation in cultures containing nitroso dapsone (30µM), autologous EBV-transformed B-cells and T-cell clones. Left hand graph shows the standard curve for dapsone (concentration range: 5nM-1µM). Right hand side graph shows the time-dependent formation of dapsone.

**Figure 4. Dapsone and nitroso dapsone activate T-cell clones at the same minimum concentration.** (a) Dapsone- and (b) nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with irradiated autologous EBV-transformed B-cells and either dapsone (0.1-100µM) or the nitroso metabolite (0.1-100µM) in triplicate cultures for 48h. T-cell proliferative responses were assessed through the addition of [3H]-thymidine. Representative weakly and strongly cross-reactive dapsone and nitroso dapsone-responsive clones are shown.

**Figure 5: Antigen presenting cells are required for the activation of dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones.** (a) Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with dapsone (500µM) or the nitroso metabolite (20µM) in triplicate cultures for 48h either in the presence or absence of autologous EBV-transformed B-cells. (b) Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with antigen presenting cells and dapsone (500µM) or the nitroso metabolite (20µM) in triplicate cultures for 48h either in the presence or absence of anti-HLA class I and II blocking antibodies. [3H]-thymidine was added for 16h to measure drug-specific proliferative responses.

**Figure 6. Dapsone and nitroso dapsone activate T-cells via different pathways.** (a) Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with dapsone or the nitroso metabolite in the presence of either irradiated or glutaraldehyde-fixed autologous EBV-transformed B-cells (APC, antigen presenting cells) in triplicate cultures for 48h. Fixation blocks antigen processing. (b) Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with drug- or drug metabolite-pulsed (0.5-2h) irradiated autologous EBV-transformed B-cells in the absence of soluble drug in triplicate cultures for 48h. T-cell proliferative responses were assessed through the addition of [3H]-thymidine.

**Figure 7.** **Dapsone and nitroso dapsone bind with a degree of selectively to HLA-B\*13:01 to activate certain CD8+ T-cell clones.** (a)Nitroso dapsone- and (b) dapsone-responsive CD8+ clones were cultured with drug or drug metabolite and irradiated EBV-transformed B-cells (APC, antigen presenting cells) from 10 donors expressing different HLA-B alleles in triplicate cultures for 48h. The complete HLA type of the different donors is shown in Supplementary Table 2. (c) Dapsone-responsive CD8+ clones were cultured with dapsone and irradiated EBV-transformed B-cells from 6 hypersensitive patients expressing HLA-B\*13:01 in triplicate cultures for 48h. T-cell proliferative responses were assessed through the addition of [3H]-thymidine.

**Tables.**

**Table 1. Patients’ demographics and details of the hypersensitivity reaction**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient ID** | **Gender** | **Age (years)** | **Medication history** | **Onset of symptoms (days)** | **Clinical presentation** | **Skin patch test** |
| 1 | Female | 43 | Dapsone, rifampin, and clofazimine | 3 | Fever, rash, and abnormal liver function tests | - |
| 3 | Female | 25 | Dapsone, rifampin, and clofazimine | 28 | Fever, rash, and abnormal liver function tests | - |
| 5 | Male | 39 | Dapsone, rifampin, and clofazimine | 30 | Fever | + |
| 6 | Male  | 41 | Dapsone, rifampin, and clofazimine. | 48 | Fever, rash, and lymphadenopathy | + |
| 7 | Male  | 54 | Dapsone, rifampin, and clofazimine | 16 |  Fever, rash, and abnormal liver function tests (AST 47.7 U/L; ALP132.3 U/L) | - |
| 8 | Female | 27 | Dapsone, rifampin, and clofazimine | 17 | Fever and abnormal liver function tests (AST 56.3 U/L; ALP 225.7 U/L; GGT 184.8 U/L; TBIL 38.8 umol/L; DBIL 21.3 umol/L; IBIL 17.5) | + |

**Table 2: Phenotype and drug specificity of T-cell clones generated from dapsone hypersensitive patients.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Phenotype & drug specificity** | **Total Number of clones** | **Number of drug-specific clones** | **Percentage of responding clones (%)** |
| **Patient 8** |
| CD4+, DDS+ | 236 | 176 | 74.58 |
| CD8+, DDS+ | 245 | 29 | 11.84 |
| CD4+, DDS-NO+ | 384 | 210 | 54.69 |
| CD8+, DDS-NO+ | 304 | 54 | 17.76 |
| **Patient 6** |
| CD4+, DDS+ | 177 | 76 | 42.94 |
| CD8+, DDS+ | 178 | 14 | 7.87 |
| CD4+, DDS-NO+ | 208 | 57 | 27.40 |
| CD8+, DDS-NO+ | 285 | 15 | 5.26 |
| **Patient 5** |
| CD4+, DDS+ | 180 | 64 | 35.56 |
| CD8+, DDS+ | 170 | 36 | 21.18 |
| CD4+, DDS-NO+ | 149 | 43 | 28.86 |
| CD8+, DDS-NO+ | 192 | 20 | 10.42 |

**Supplementary Text**

**Generation of drug-specific T-cell clones**

PBMC (1-5x106/ml) from hypersensitive patients 5, 6 and 8 were incubated with dapsone (125-250µM) and nitroso dapsone (10-20µM) in IL-2 (100IU/ml) containing medium to generate T-cell lines. Culture medium consisted of RPMI-1640 supplemented with pooled heat-inactivated human AB serum (10%, v/v), HEPES (25mM), L-glutamine (2mM), transferrin (25μg/mL), streptomycin (100μg/mL), and penicillin (100U/mL). After 14 days, T-cells were serially diluted (0.3-3 cells/well), and subjected to PHA-driven expansion (5µg/ml). Irradiated allogeneic PBMC (5x104/well) were added as feeder cells. After 28 days, clones expanded to approximately 5x105 cells were tested for drug specificity by culturing dapsone (250µM; 200µl total volume) or nitroso dapsone (20µM) with clones (5x104 cells/well) and irradiated Epstein-Barr virus (EBV)-transformed B-cells (1x104 cells/well) for 48h in triplicate cultures per experimental condition. EBV-transformed B-cell lines were generated from autologous PBMC by culturing the PBMC with supernatant from the B9-58 cell line containing cyclosporine A. The EBV-transformed B-cell lines were used as antigen presenting cells. Proliferation was measured by the addition of [3H]thymidine for 16h followed by scintillation counting. Clones with a stimulation index (SI) (mean cpm drug-treated wells / mean cpm in control wells) of greater than 2 were expanded and analysed further.

**Phenotype and specificity testing of drug-specific T-cell clones**

Cell phenotyping was performed by flow cytometry. TCR Vβ expression was measured using the IOTest® Beta Mark, TCR Vβ Repertoire Kit (Beckman Coulter). Antibodies used for flow cytometry staining purchased from BD Biosciences (Oxford, UK) were CD4-APC (clone RPA T4), CD8-PE (clone HIT8a), CCR4-PE (clone 1G1), CLA-FITC (clone HECA-452); and from R&D Systems (Abingdon, UK) were CCR1-Alex Fluor 488 (clone 53504), CCR2-PE (clone 48607), CCR3-FITC (clone 61828), CCR5-FITC (clone CTC5), CCR6-APC (Clone 53103), CCR8-PE (clone 191704),  CCR9-APC (clone 248621), CCR10-PE (clone 314305), CXCR1-FITC (clone 42705), CXCR3-APC (clone 49801), CXCR6-PE (clone 56811) and E cadherin-Alexa Fluor 488 (clone 180224). Approximately 1x105 T cell clones were stained for surface markers using directly-conjugated antibodies. The cells were incubated on ice for 20 min and then washed with 1ml 10% foetal calf serum in Hanks balanced salt solution. Chemokine receptor expression is presented as mean fluorescence intensity of the whole population of each clone. All cells were acquired using a FACS Canto II (BD Biosciences, Oxford, UK) and data analyzed by Cyflogic. A minimum of 50,000 cells were acquired using FSC/SSC characteristics.

Dose-dependent proliferative responses and the profile of secreted cytokines (IFN-γ, IL-5, IL-13, granzyme B, Fas L, perforin, IL-17 and IL22) from CD4+ and CD8+ clones were measured using [3H]thymidine and ELIspot, respectively. The ELIspot reader accurately counts spots up to approximately 400-500; thus, giving an upper limit to the assay. In both experiments T-cell clones (5x104) were cultured with irradiated antigen presenting cells (1x104) and dapsone (0.01-500µM) or nitroso dapsone (0.01-100µM; 200µl) for 48 h.

Dapsone- and nitroso dapsone-responsive clones (5x104) were also cultured with non-toxic concentrations of structurally-related compounds (sulfamethoxazole, sulfamerazine, sulfadiazine, sulfachloropyridazine, sulfadoxin, sulphanilamide, 4,4 thiodianiline, 4,4 oxyaniline, 3,3 sulfonyldianiline and mono and diacetylated forms of dapsone) and antigen presenting cells (1x104; 200µl) for 48h. Proliferation was measured by the addition of [3H]thymidine followed by scintillation counting.

**Pathways of drug presentation to T-cells**

To explore the pathway of CD4+ and CD8+ T-cell activation with dapsone and nitroso dapsone, T-cell clones were subjected to a variety of experimental protocols. First, clones were cultured with optimal concentrations of dapsone or nitroso dapsone in the presence or absence of antigen presenting cells. Second, clones were cultured with dapsone or nitroso dapsone and antigen presenting cells in the presence or absence of isotype (IgG1) or MHC class I (DX17) and class II (Tu39) blocking antibodies were purchased from BD Biosciences. Third, clones were cultured with dapsone or nitroso dapsone and glutaraldehyde-fixed antigen presenting cells. Fixation blocks protein processing. Briefly, EBV-transformed B-cells (2×106 cells/ml) were washed in HBSS buffer to exclude FBS and re-suspended in HBSS buffer (1 ml). Glutaraldehyde (25%, 1 µL) was added to the cells and gently mixed for 30 secs. Glycine (1ml of 1 M) was quickly added to the cell suspension and mixed for a further 45 secs. Cells were washed three times to remove glutaraldehyde and then resuspend in T-lymphocyte culture medium. This was followed by co-culture of drug-specific T-cell clones (5×104, 50 µL) with glutaraldehyde-fixed EBV-transformed B-cells (1×104 cells, 50 µL) in the presence or absence of the drug antigen (100 µL) in a 96-well U-bottom microplate for 48 hrs, 5% CO2 at 37˚C. [3H]-thymidine was added for the final 16 hours of incubation to evaluate T-lymphocyte proliferation. Fourth, antigen presenting cells pulsed with dapsone or nitroso dapsone for 0.5-2h were used to activate T-cells in the absence of soluble drug. Fifth, clones were cultured with dapsone or nitroso dapsone and antigen presenting cells in the presence or absence of glutathione (1mM). Glutathione binds covalently to aromatic nitroso compounds, limiting their protein reactivity (24). The stability of dapsone and nitroso dapsone and the formation of dapsone glutathione adducts during the culture period were measured by mass spectrometry. Briefly, aliquots of cell culture supernatant (20 µL) and the calibration standards (20 µL) were diluted with LC-MS grade water (1:10 dilution) and deproteinized with acetonitrile. The extracts were evaporated to dryness in a Speed Vac and reconstituted in 200 µL water. 5 µL samples and standards were analysed immediately by a Triple QuadTM 6500 mass spectrometer (AB Sciex,) coupled with a 1260 Infinity LC system (Agilent Technologies, Germany). The multiple reaction monitoring transitions for each analyte were as following: dapsone 249.1/156.1 and 249.1/107.9; azoxy dapsone, 509.1/108.1 and 509.1/156.1; dapsone-GSH (3O), 602.1/401.3, 602.1/156.1, and 602.1/261.5. Other MS parameters, such as voltage potential and collision energy were optimised to achieve greatest sensitivity. Data acquisition and quantification were performed using Analyst 1.5 software and Multi-Quant 3.0 (AB Sciex).

**The involvement of HLA-B\*13:01 in the activation of CD8+ T-cell clones**

To explore whether dapsone and nitroso dapsone interact with HLA-B\*13:01 to activate CD8+ clones, EBV-transformed B-cells were generated from 9 healthy donors expressing HLA alleles displaying at least 90% similarity to HLA-B\*13:01 (Supplementary Table 2). EBV-transformed B-cells from one additional hypersensitive patient expressing HLA-B\*13:01 itself were also used (Supplementary Table 3). CD8+ T-cell clones were cultured with the different antigen presenting cells and dapsone or nitroso dapsone for 48h. Proliferation was measured by the addition of [3H]thymidine followed by scintillation counting.

**Supplementary Table 1. HLA typing of hypersensitive patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | HLA-A1 | HLA-B | HLA-C | HLA-DQB1 | HLA-DRB1 |
| Patient 1 | 02:07 | 24:02 | *13:01* | 40:01 | 03:04 | 15:02 | 03:01 | 06:01 | 11:01 | 15:01 |
| Patient 5 | 02:07 | 11:01 | *13:01* | 40:01 | 03:04 | 07:02 | 06:01 | 06:01 | 08:03 | 15:01 |
| Patient 6 | 02:07 | 11:01 | *13:01* | 46:01 | 01:02 | 03:04 | 06:01 | 06:10 | 15:01 | 15:01 |
| Patient 7 | 11:01 | 11:01 | *13:01* | 15:32 | 03:04 | 12:03 | 03:01 | 03:01 | 11:06 | 13:12 |
| Patient 8 | 11:01 | 24:02 | *13:01* | 15:25 | 03:04 | 04:03 | 03:01 | 05:02 | 12:02 | 15:01 |

1 Patient 3 PBMC were not available for HLA typing

**Supplementary Table 2. HLA typing of antigen presenting cells from healthy donors**

|  |  |  |
| --- | --- | --- |
| **Alleles with ↑ 90% amino acid B\*13:01 match** | **Sequence similarity** | **HLA alleles expressed on antigen presenting cells from healthy donors** |
| **HLA-A** | **HLA-B** | **HLA-C** | **HLA-DRB1** | **HLA-DQB1** | **HLA-DQA1** |
| **Donor 1 (B\*08:01)** | 91.7 | 01:01 | 01:01 | *08:01* | *57:01* | 07:01 | 07:01 | 04:04 | 07:01 | 03:03 | 04:02 | 02:01 | 03:01 |
| **Donor 2 (B\*13:02)** | 99.2 | 02:01 | 30:01 | *13:02* | *57:01* | 06:02 | 7:01 | 07:01 | 07:01 | 02:01 | 03:03 | 02:01 | 02:01 |
| **Donor 3 (B\*15:01)** | 93.9 | 01:01 | 03:01 | *15:01* | *57:01* | 03:03 | 6:02 | 04:01 | 07:01 | 03:02 | 03:03 | 02:01 | 03:01 |
| **Donor 4 (B\*35:01)** | 94.5 | 03:01 | 26:01 | *35:01* | *35:01* | 04:01 | 4:01 | 01:01 | 11:01 | 03:01 | 05:01 | 01:01 | 05:01 |
| **Donor 5 (B\*40:01)** | 93.4 | 02:01 | 03:02 | *40:01* | *51:01* | 03:04 | 4:02 | 11:04 | 11:01 | 03:01 | 03:01 | 05:01 | 05:01 |
| **Donor 6 (B\*44:02)** | 96.7 | 02:01 | 02:01 | *44:02* | *57:01* | 05:01 | 06:02 | \*04:01 | 07:01 | 03:01 | 03:03 | 02:01 | 03:01 |
| **Donor 7 (B\*46:01)** | 92.3 | 11:01 | 24:02 | *46:01* | *58:01* | 01:02 | 03:02 | 03:01 | 09:01 | 02:01 | 03:03 | 03:01 | 05:01 |
| **Donor 8 (B\*51:01)** | 94.2 | 11:01 | 11:01 | *51:01* | *52:04* | 04:01 | 12:02 | 04:02 | 14:04 | 03:02 | 05:03 | 01:01 | 03:01 |
| **Donor 9 (B\*58:01)** | 94.2 | 02:06 | 02:01 | *15:01* | *58:01* | 01:02 | 07:01 | 13:02 | 15:01 | 06:09 | 06:02 | 01:02 | 01:02 |
| **Donor 101 (B\*13:01)** | 100 |  |  | *13:01* |  |  |  |  |  |  |  |  |  |

1 Antigen presenting cells from hypersensitive patients 5, 6 or 8 were used. See Table E2 for HLA typing data.

**Supplementary Table 3. Cytokine secretion from dapsone and nitroso dapsone-responsive CD4+ and CD8+ T-cell clones.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **IFN-γ** | **IL-5** | **IL-13** | **IL-17** | **IL-22** | **Per-forin** | **Granz-yme B** | **Fas L** |
| CD4 | DDS | 1001 | 88 | 82 | 0 | 100 | 94 | 94 | 92 |
| DDS-NO | 80 | 100 | 60 | 0 | 100 | 60 | 80 | 92 |
| CD8 | DDS | 100 | 79 | 57 | 0 | 78 | 93 | 78 | 100 |
| DDS-NO | 100 | 100 | 100 | 0 | 90 | 100 | 100 | 100 |

1 Numbers refer to the percentage of clones with an increase of at least 50 spot forming units (sfu) when drug (DDS, dapsone; DDS-NO, nitroso dapsone)- and vehicle-treated wells were compared.

**Supplementary Figures**

**Supplementary Figure 1. Dapsone- and nitroso dapsone-specific stimulation of PBMC from HLA-B\*13:01+ dapsone tolerant patients.** PBMC from patients were exposed to graded concentrations of dapsone or nitroso dapsone. Proliferation was measured after 5 days by the addition of [3H]thymidine for 16h. Replicates were performed in triplicate. Results are expressed as mean±SD cpm from 4 donors.

**Supplementary Figure 2. Generation of dapsone- and nitroso dapsone-responsive CD4+ and CD8+ T-cell clones.** Clones were generated from dapsone and nitroso dapsone CD4+ or CD8+ T-cell lines by serial dilution and repetitive mitogen stimulation.Well-growing clones were cultured with autologous antigen presenting cells and either dapsone or nitroso dapsone in triplicate cultures for 48h. Proliferative responses were measured by the addition of [3H]thymidine. Clones with a stimulation index (SI) of 2 or above were expanded further for phenotypic analysis and mechanistic studies.

**Supplementary Figure 3. Crossreactivity of dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones with dapsone hydroxylamine, analogues and sulfonamide antimicrobials.** (a) Dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones were cultured with irradiated autologous EBV-transformed B-cells and non-toxic concentrations of the test compounds in triplicate cultures for 48h. T-cell proliferative responses were assessed through the addition of [3H]-thymidine. (b) Structure of the test compounds.

**Supplementary Figure 4. T-cell receptor Vβ chains and chemokine receptors expressed on dapsone- and nitroso dapsone-responsive CD4+ and CD8+ clones.** (a)TCR Vβ expression was measured with the IOTest® Beta Mark, TCR Vβ Repertoire Kit, which covers over 80% of the available TCRs, by flow cytometry. (b) Chemokine receptors were measured on resting clones by flow cytometry. Expression is presented as mean fluorescence intensity of the whole population of each clone. (c) Representative flow cytometry traces of a single clone showing CD4/8 staining and expression of a single T-cell receptor Vβ.

**Supplementary Figure 5. Glutathione inhibits the activation of T-cell clones with nitroso dapsone.** (a) Semi-quantitative analysis of the levels of nitroso dapsone glutathione conjugate formed in incubations containing EBV-transformed B-cells in medium alone, medium containing nitroso dapsone or nitroso dapsone and glutathione (1mM). SupplementaryFigure 5 contains the mass spectrometric images.(b) Nitroso dapsone-responsive clones were cultured with (i) irradiated autologous EBV-transformed B-cells, soluble drug metabolite and glutathione, and (ii) drug metabolite-pulsed (2h) irradiated autologous EBV-transformed B-cells (±glutathione) in triplicate cultures for 48h. Glutathione was added to cells before nitroso dapsone in both assays. T-cell proliferative responses were assessed through the addition of [3H]-thymidine.

**Supplementary Figure 6. Mass spectrometric analysis of the nitroso dapsone glutathione adduct formed in culture medium.** EBV-transformed B cells were cultured with either (a) medium only, (b) medium containing nitroso dapsone or (c) nitroso dapsone in the presence of glutathione (1mM).

**References**

1. Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: Key regulators of T-cell-mediated drug hypersensitivity. *HLA* 2018; **91**:3-16.

2. Teh LK, Selvaraj M, Bannur Z, Ismail MI, Rafia H, Law WC, et al. Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B\*15:02. *J Pharm Pharm Sci* 2016; **19**:147-160.

3. Van Den Driessche G, Fourches D. Adverse drug reactions triggered by the common HLA-B\*57:01 variant: a molecular docking study. *J Cheminform* 2017; **9**:13.

4. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B\*5701 screening for hypersensitivity to abacavir. *N Engl J Med* 2008; **358**:568-579.

5. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B\*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet* 2009; **41**:816-819.

6. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature* 2004; *428*:486.

7. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B\*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci U S A* 2005; **102**:4134-4139.

8. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. Human leukocyte antigen (HLA)-B\*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. *Hepatology* 2013; **57**:727-739.

9. Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B\*58:01. *J Immunol* 2014; **192**:2984-2993.

10. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. *Nature* 2012; **486**:554-558.

11. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. *Proc Natl Acad Sci U S A* 2012; **109**:9959-9964.

12. Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. *J Allergy Clin Immunol* 2011; **128**:1266-1276.

13. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. *J Allergy Clin Immunol* 2004; **114**:1209-1215.

14. Castrejon JL, Berry N, El-Ghaiesh S, Gerber B, Pichler WJ, Park BK, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. *J Allergy Clin Immunol* 2010; **125**:411-418.

15. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. *J Immunol* 2000; **164**:6647-6654.

16. Alzahrani A, Ogese M, Meng X, Waddington JC, Tailor A, Farrell J, et al. Dapsone and Nitroso Dapsone Activation of Naive T-Cells from Healthy Donors. *Chem Res Toxicol* 2017; **30**:2174-2186.

17. Roychowdhury S, Vyas PM, Svensson CK. Formation and uptake of arylhydroxylamine-haptenated proteins in human dendritic cells. *Drug Metab Dispos* 2007; **35**:676-681.

18. Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, Lamba JK, Schuetz EG, et al. Enzyme-mediated protein haptenation of dapsone and sulfamethoxaozle in human keratinocytes - 1. Expression and role of cytochromes P450. *J Pharmacol Exp Ther* 2006; **319**:488-496.

19. Rao PN, Lakshmi TS. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal. *Lepr Rev* 2001; **72**:57-62.

20. Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, et al. HLA-B\*13:01 and the dapsone hypersensitivity syndrome. *N Engl J Med* 2013; **369**:1620-1628.

21. Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B\*13: 01 allele in the Thai population. *Pharmacogenet Genomics* 2017; **27**:429-437.

22. Watanabe H, Watanabe Y, Tashiro Y, Mushiroda T, Ozeki T, Hashizume H, et al. A docking model of dapsone bound to HLA-B\*13:01 explains the risk of dapsone hypersensitivity syndrome. *J Dermatol Sci* 2017; **88**:320-329.

23. Chen WT, Wang CW, Lu CW, Chen CB, Lee HE, Hung SI, et al. The function of HLA-B\*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. *J Invest Dermatol* 2018; 138:1546-1554.

24. Naisbitt DJ, ONeill PM, Pirmohamed M, Park BK. Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: Implications for immune mediated toxicity. *Bioorganic & Medicinal Chemistry Letters* 1996; **6**:1511-1516.

25. Ellis MK, Hill S, Foster PM. Reactions of nitrosonitrobenzenes with biological thiols: identification and reactivity of glutathion-S-yl conjugates. *Chem Biol Interact* 1992; **82**:151-163.

26. von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. *Int Immunol* 2001; **13**:877-885.

27. Zanni MP, von Greyerz S, Schnyder B, Wendland T, Pichler WJ. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific àá+ T cell clones. *Int Immunol* 1998; **10**:507-515.

28. Uetrecht J, Naisbitt DJ. Idiosyncratic Adverse Drug Reactions: Current Concepts. *Pharmacological Reviews* 2013; **65**:779-808.

29. Kenna JG, Knight TL, van Pelt FN. Immunity to halothane metabolite-modified proteins in halothane hepatitis. *Ann N Y Acad Sci* 1993; **685**:646-661.

30. You Q, Cheng L, Ju C. Generation of T cell responses targeting the reactive metabolite of halothane in mice. *Toxicol Lett* 2010; **194**:79-85.

31. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. *Chem Res Toxicol* 1998; **11**:969-988.

32. Bergstrom MA, Ott H, Carlsson A, Neis M, Zwadlo-Klarwasser G, Jonsson CA, et al. A skin-like cytochrome P450 cocktail activates prohaptens to contact allergenic metabolites. *J Invest Dermatol* 2007; **127**:1145-1153.

33. Sachs B, Erdmann S, Al-Masaoudi T, Merk HF. In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. *Br J Dermatol* 2001; **144**:316-320.

34. Naisbitt DJ, O'Neill PM, Pirmohamed M, Park BK. Synthesis and reactions of nitroso sulfamethoxazole with biological nucleophiles - implications for immune-mediated toxicity. *Bioorg Med Chem Let* 1996; **6**:1511-1516.

35. Alfirevic A, Vilar FJ, Alsbou M, Jawaid A, Thomson W, Ollier WE, et al. TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. *Pharmacogenomics* 2009; **10**:531-540.

36. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genomics* 2008; **18**:99-107.

37. Bell CC, Faulkner L, Martinsson K, Farrell J, Alfirevic A, Tugwood J, et al. T-cells from HLA-B\*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. *Chem Res Toxicol* 2013; **26**:759-766.

38. Adam J, Eriksson KK, Schnyder B, Fontana S, Pichler WJ, Yerly D. Avidity determines T-cell reactivity in abacavir hypersensitivity. *Eur J Immunol* 2012; **42**:1706-1716.

39. Lucas A, Lucas M, Strhyn A, Keane NM, McKinnon E, Pavlos R, et al. Abacavir-reactive memory T cells are present in drug naive individuals. *PLoS One* 2015; 10:e0117160.

40. Castrejon JL, Lavergne SN, El-Sheikh A, Farrell J, Maggs JL, Sabbani S, et al. Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives. *Chem Res Toxicol* 2010; **23**:184-192.

41. Burkhart C, von Greyerz S, Depta JP, Naisbitt DJ, Britschgi M, Park KB, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. *Br J Pharmacol* 2001; **132**:623-630.

42. Pichler WJ. Delayed drug hypersensitivity reactions. *Ann Intern Med.* 2003; **139**:683-93.

43 Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, et al. beta-Lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. *J Allergy Clin Immunol* 2018; **141**:235-49.

44. Gibson A, Ogese M, Sullivan A, Wang E, Saide K, Whitaker P, et al. Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function. *J Immunol* 2014; **192**:2611-2621.

45. Xia M, Hu S, Fu Y, Jin W, Yi Q, Matsui Y, et al. CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin. *J Allergy Clin Immunol* 2014; **134**:634-644.